mRNA vaccines against influenza in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial gives each healthy adult participant a single dose of one experimental mRNA influenza vaccine or a licensed comparator and follows them for about six months. Safety is monitored and blood samples are collected at three scheduled visits to measure immune responses, with a nasal swab taken at the first visit. Multiple vaccine candidates are being compared to understand which formulations produce the strongest antibody response and acceptable safety profiles. The trial is sponsored by a major pharmaceutical company and conducted at several U.S. clinical sites.

Why it matters

Who can join: the full rules

Inclusion Criteria

• Healthy and medically stable participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study.

Exclusion Criteria

* Tested positive for influenza ≤5 months (150 days) prior to Visit 1 (Day 1).
* Vaccination with any investigational or licensed influenza vaccine ≤5 months (150 days) before Visit 1 (Day 1).
* Receipt of antiviral therapies for influenza (eg, Tamiflu) ≤5 months (150 days) prior to Visit 1 (Day 1).

Where it's running

• AMR Clinical
  Mobile, Alabama, United States Recruiting
• Diablo Clinical Research, LLC d/b/a Flourish Research
  Walnut Creek, California, United States Recruiting
• Clinical Research Consulting, LLC
  Milford, Connecticut, United States Recruiting
• George Washington Medical Faculty Associates
  Washington D.C., District of Columbia, United States Recruiting
• Indago Research & Health Center, Inc
  Hialeah, Florida, United States Recruiting
• Palm Springs Community Health Center
  Miami Lakes, Florida, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Marstacimab for mild to moderate hemophilia A or B in people without inhibitors

  This study tests whether weekly injections of marstacimab can reduce bleeding in adolescents and adults with mild to moderate hemophilia A or B who don’t have inhibitors.

  Recruiting Phase 3 Pfizer · Flowood, Mississippi · NCT07923981

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Berobenatide in adults with sleep apnea and obesity who don’t use a PAP machine

  This study tests berobenatide versus placebo in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity who are not using PAP therapy.

  Recruiting at 3 sites Phase 3 Pfizer · Cullman, Alabama and 3 other locations · NCT07881757

• Berobenatide: how it enters the blood after different delivery methods in adults with overweight or obesity

  This study tests a single dose of Berobenatide to see how it behaves in the body when given in different delivery forms to adults with overweight or obesity.

  Recruiting Phase 1 Pfizer · Anaheim, California · NCT07876531

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.